247 related articles for article (PubMed ID: 36267791)
1. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
2. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment.
Dai G; He L; Yan Q; Li Y; Huang Y; Li B; Wang G
Front Oncol; 2023; 13():1167516. PubMed ID: 37456237
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract][Full Text] [Related]
6. Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report.
Jin C; Yang B
Case Rep Oncol; 2020; 13(2):601-605. PubMed ID: 32595469
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review.
Li J; Liang H; He J; Sui X; Qin Y
Front Oncol; 2021; 11():639168. PubMed ID: 34046343
[TBL] [Abstract][Full Text] [Related]
8. A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy.
Cai R; Liu Y; Sha H; Yu J; Fang Y; Zhou G; Shen B
Heliyon; 2023 Nov; 9(11):e21902. PubMed ID: 38027958
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review.
Wen Y; Dong Y; Yi L; Yang G; Xiao M; Li Q; Zhao C; Ye D; Yao Y
Front Oncol; 2023; 13():1241475. PubMed ID: 37920159
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
Qian X; Wang Y; Liu F; Yuan Y; Fang C; Zhang X; Yuan S; Chen R; Yu B; Wang T; Yin Y; Li Y
Front Immunol; 2022; 13():956982. PubMed ID: 36389780
[TBL] [Abstract][Full Text] [Related]
11. Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report.
Wang M; Gong Y; Cheng Y; Yang L; Wang W; Lei X
Oncol Lett; 2022 Oct; 24(4):343. PubMed ID: 36072009
[TBL] [Abstract][Full Text] [Related]
12. Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB
Huang N; Qu T; Zhang C; Li J
Front Oncol; 2024; 14():1269148. PubMed ID: 38414747
[TBL] [Abstract][Full Text] [Related]
13. Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review.
Wang L; Huang Y; Sun X
Front Oncol; 2024; 14():1362160. PubMed ID: 38725630
[TBL] [Abstract][Full Text] [Related]
14. Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers.
Ding K; Peng Z; Xu Y
Ther Adv Med Oncol; 2024; 16():17588359241249041. PubMed ID: 38716479
[TBL] [Abstract][Full Text] [Related]
15. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
Chen P; Yu M; Zhang JL; Chen WY; Zhu L; Song Y; Jiang CY; Zhang S
World J Clin Cases; 2020 Jul; 8(13):2876-2884. PubMed ID: 32742998
[TBL] [Abstract][Full Text] [Related]
16. The treatment of advanced pulmonary sarcomatoid carcinoma.
Zheng Y; Fu Y; Zhong Q; Deng R; Zhang Y
Future Oncol; 2022 Feb; 18(6):727-738. PubMed ID: 34879738
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review.
Kong F; Wang W; Gong L; Wu W; Liu Y
J Clin Pharm Ther; 2020 Dec; 45(6):1489-1496. PubMed ID: 32776600
[TBL] [Abstract][Full Text] [Related]
18. Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report.
Huang F; Tang J; Lou J; Wang Q; Ma K; Qiao R; Si J; Kang Y; Chen H; Mei J; Wang H; Liu Y; Miao L
Transl Cancer Res; 2022 Sep; 11(9):3337-3342. PubMed ID: 36237231
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation.
Cao JZ; Wu W; Pan JF; Wang HW; Jiang JH; Ma Q
Front Oncol; 2021; 11():643413. PubMed ID: 34109111
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study.
Zhou F; Guo H; Zhou X; Xie H; Tian T; Zhao W; Gao G; Xiong A; Wang L; Li W; Chen X; Zhang Y; Fan J; Wu F; Zhang Y; Zhou C
Ther Adv Med Oncol; 2022; 14():17588359221136759. PubMed ID: 36419724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]